Allworth Financial’s Karyopharm Therapeutics KPTI Stock Holding History

Allworth Financial’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$145	Hold	26	–	–	﹤0.01%	4964
2025 Q4	$192	Hold	26	–	–	﹤0.01%	4701
2025 Q3	$171	Sell	26 -6	-19%	-$32	﹤0.01%	4620
2025 Q2	$138	Hold	32	–	–	﹤0.01%	4365
2025 Q1	$192	Sell	32 -1	-3%	-$9	﹤0.01%	3878
2024 Q4	$334	Hold	33	–	–	﹤0.01%	3693
2024 Q3	$415	Hold	33	–	–	﹤0.01%	3461
2024 Q2	$445	Hold	33	–	–	﹤0.01%	3404
2024 Q1	$755	Hold	33	–	–	﹤0.01%	3164
2023 Q4	$433	Hold	33	–	–	﹤0.01%	3164
2023 Q3	$670	Hold	33	–	–	﹤0.01%	2971
2023 Q2	$895	Hold	33	–	–	﹤0.01%	2761
2023 Q1	$1.95K	Hold	33	–	–	﹤0.01%	2420
2022 Q4	$1.7K	Buy	33 +26	+371%	+$1.8K	﹤0.01%	2296
2022 Q3	$1K	Hold	7	–	–	﹤0.01%	2419
2022 Q2	$0	Hold	7	–	–	﹤0.01%	2601
2022 Q1	$1K	Hold	7	–	–	﹤0.01%	1954
2021 Q4	$1K	Hold	7	–	–	﹤0.01%	1833
2021 Q3	$1K	Hold	7	–	–	﹤0.01%	1771
2021 Q2	$1K	Sell	7 -22	-76%	-$3.19K	﹤0.01%	1467
2021 Q1	$5K	Buy	29 +22	+314%	+$4.63K	﹤0.01%	1137
2020 Q4	$2K	Buy	+7	New	+$1.62K	﹤0.01%	1170

Other funds holding KPTI

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Allworth Financial's KPTI Position: Q1 2026 in Review

Allworth Financial held its Karyopharm Therapeutics (KPTI) position steady in Q1 2026 at 26 shares worth $145. The position accounts for ﹤0.01% of the portfolio, ranked #4964.

Allworth Financial first reported a position in KPTI in Q4 2020 and has held it in 22 quarters since. The position peaked at $5K in Q1 2021. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

Allworth Financial held 26 shares of Karyopharm Therapeutics worth $145 as of Q1 2026.
Allworth Financial left its Karyopharm Therapeutics share count unchanged in Q1 2026.
Karyopharm Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q1 2026, its #4964 holding.
Allworth Financial first reported a position in Karyopharm Therapeutics in Q4 2020 and has held it in 22 quarters since.
Allworth Financial's Karyopharm Therapeutics position peaked at $5K in Q1 2021.
77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Allworth Financial's 13F filing for Q1 2026, filed 15 May 2026.